Trial
NCT02134197
Dose-escalation Study of Lupartumab Amadotin (BAY1129980)
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
—
Condition
Neoplasms
Intervention
Lupartumab Amadotin (BAY1129980)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-12-11